OncoMatch/Clinical Trials/NCT06514508
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Is NCT06514508 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Motixafortide+G-CSF for multiple myeloma.
Treatment: Motixafortide+G-CSF — This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: combination/multi-agent chemotherapy (carfilzomib, lenalidomide, dexamethasone, bortezomib, pomalidomide) — induction
At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
Cannot have received: autologous or allogeneic hematopoietic cell transplantation
Previous history of autologous or allogeneic-HCT.
Cannot have received: radioimmunotherapy (radionuclides)
Received prior treatment with radioimmunotherapy (e.g. radionuclides).
Cannot have received: BCL2 inhibitor (venetoclax)
Received prior treatment with venetoclax.
Lab requirements
Blood counts
Adequate organ function at screening.
Kidney function
Adequate organ function at screening.
Liver function
Adequate organ function at screening.
Adequate organ function at screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06514508 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous or allogeneic hematopoietic cell transplantation, radioimmunotherapy, BCL2 inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 78 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages